[1]
|
Coffin, B. (2013) Quel est l’impact du Syndrome de l’Intestin Irritable sur la qualité de vie des patients? [What Is the Impact of Irritable Bowel Syndrome on Patients’ Quality of Life?] Hepato Gastro, 20, 11-15.
|
[2]
|
Gourcerol, G., Melchior, C., Leroi, A.M. and Ducrotté, P. (2013) Traitement du syndrome de l’intestin irritable: où en est-on? [Management of Irritable Bowel Syndrome: Current Status and Future Perspective.] Hepato-Gastro, 20, 752-765.
|
[3]
|
Ducroté, P. (2011) Microbiote et syndrome de l’intestin irritable. [Microbiota and Irritable Bowel Syndrome.] Lettre de l’hépato-gastroentérologue, XIV, 154-159.
|
[4]
|
Longstreth, G.F., Thompson, W.G., Chey, W.D., Houghton, L.A., Mearin, F. and Spiller, R.C. (2006) Functional Bowel Disorders. Gastroenterology, 130, 1480-1491.
https://doi.org/10.1053/j.gastro.2005.11.061
|
[5]
|
Drossman, D.A., Li, Z., Andruzzi, E., et al. (1993) U.S. Householder Survey of Functional Gastrointestinal Disorders: Prevalence, Sociodemography, and Health Impact. Digestive Diseases and Sciences, 38, 1569-1580.
https://doi.org/10.1007/BF01303162
|
[6]
|
Camilleri, M. and, Andresen, V. (2009) Current and Novel Herapeutic Options for Irritable Bowel Syndrome Management. Digestive and Liver Disease, 41, 854-862.
https://doi.org/10.1016/j.dld.2009.07.009
|
[7]
|
Hammerle, C.W. and Surawicz, C.M. (2008) Updates on Treatment of Irritable Bowel Syndrome. World Journal of Gastroenterology, 14, 2639-2649.
https://doi.org/10.3748/wjg.14.2639
|
[8]
|
El-Serag, H.B. (2003) Impact of Irritable Bowel Syndrome, Prevalence and Effect on Health Related Quality of Life. Reviews in Gastroenterological Disorders, 3, S3-S11.
|
[9]
|
Lembo, A.J. (2015) New and Emerging Treatment Options for Irritable Bowel-Syndrome Current and Emerging Therapies for Irritable Bowel Syndrome. Gastroenterology & Hepatology, 11, 9-15.
|
[10]
|
Bajaj, J., Heuman, D., Sanyal, A., Hylemon, P., Sterling, R., Stravitz, R. et al. (2013) Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy. PLoS One, 8, e60042.
https://doi.org/10.1371/journal.pone.0060042
|
[11]
|
Brown, E., Xue, Q., Jiang, Z., Xu, Y. and DuPont, H. (2010) Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles. Antimicrob Agents Chemother, 54, 388-396.
https://doi.org/10.1128/AAC.00691-09
|
[12]
|
Cheng, J., Shah, Y., Ma, X., Pang, X., Tanaka, T., Kodama, T., et al. (2010) Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation. Journal of Pharmacology and Experimental Therapeutics, 335, 32-41. https://doi.org/10.1124/jpet.110.170225
|
[13]
|
Debbia, E., Maioli, E., Roveta, S. and Marchese, A. (2008) Effects of Rifaximin on Bacterial Virulence Mechanisms at Supra- and Sub-Inhibitory Concentrations. Journal of Chemotherapy, 20, 186-194. https://doi.org/10.1179/joc.2008.20.2.186
|
[14]
|
Hopkins, K., Mushtaq, S., Richardson, J., Doumith,M., de Pinna, E., Cheasty, T., et al. (2014) In Vitro Activity of Rifaximin against Clinical Isolates of Escherichia coli and Other Enteropathogenic Bacteria Isolated from Travellers Returning to the UK. International Journal of Antimicrobial Agents, 45, 431-437.
|
[15]
|
Jiang, Z., DuPont, H., La Rocco, M. and Garey, K. (2010) In Vitro Susceptibility of Clostridium difficile to Rifaximin and Rifampin in 359 Consecutive Isolates at a University Hospital in Houston, Texas. Journal of Clinical Pathology, 63, 355-358.
https://doi.org/10.1136/jcp.2009.071688
|
[16]
|
Jiang, Z., Ke, S. and DuPont, H. (2010) Rifaximininduced Alteration of Virulence of Diarrhoea-Producing Escherichia coli and Shigella sonnei. International Journal of Antimicrobial Agents, 35, 278-281.
|
[17]
|
Maccaferri, S., Vitali, B., Klinder, A., Kolida, S., Ndagijimana, M., Laghi, L., et al. (2010) Rifaximin Modulates the Colonic Microbiota of Patients with Crohn’s Disease: An in Vitro Approach using a Continuous Culture Colonic Model System. Journal of Antimicrobial Chemotherapy, 65, 2556-2565.
https://doi.org/10.1093/jac/dkq345
|
[18]
|
Mencarelli, A., Migliorati, M., Barbanti, M., Cipriani,S., Palladino, G., Distrutti, E., et al. (2010) Pregnane-X-Receptor Mediates the Anti-Inflammatory Activities of Rifaximin on Detoxification Pathways in Intestinal Epithelial Cells. Biochemical Pharmacology, 80, 1700-1707.
|
[19]
|
Mencarelli, A., Renga, B., Palladino, G., Claudio, D., Ricci, P., Distrutti, E., et al. (2011) Inhibition of NF-kB by a PXR-Dependent Pathway Mediates Counter-Regulatory Activities of Rifaximin on Innate Immunity in Intestinal Epithelial Cells. European Journal of Pharmacology, 668, 317-324.
|
[20]
|
Schrodt, C., McHugh, E., Gawinowicz, M., DuPont, H. and Brown, E. (2013) Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis. PLoS ONE, 8, e68550. https://doi.org/10.1371/journal.pone.0068550
|
[21]
|
Terc, J., Hansen, A., Alston, L. and Hirota, S. (2014) Pregnane X Receptor Agonists Enhance Intestinal Epithelial Wound Healing and Repair of the Intestinal Barrier Following the Induction of Experimental Colitis. European Journal of Pharmaceutical Sciences, 55, 12-19.
|
[22]
|
Xu, D., Gao, J., Gillilland, M., III, Wu, X., Song, I., Kao, J., et al. (2014) Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats. Gastroenterology, 146, 484-496.
https://doi.org/10.1053/j.gastro.2013.10.026
|
[23]
|
Foxx-Orenstein, A.E. (2016) New and Emerging Therapies for the Treatment of Irritable Bowel Syndrome: An Update for Gastroenterologists. Therapeutic Advances in Gastroenterology, 9, 354-375. https://doi.org/10.1177/1756283X16633050
|
[24]
|
Di Stefano, M., Tana, P., Mengoli, C., Miceli, E., Pagani, E. and Corazza, G. (2011) Colonic Hypersensitivity Is a Major Determinant of the Efficacy of Bloating Treatment in Constipation-Predominant Irritable Bowel Syndrome. Internal and Emergency Medicine, 6, 403-411. https://doi.org/10.1007/s11739-010-0496-0
|
[25]
|
Pimentel, M., Park, S., Mirocha, J., Kane, S.V. and Kong, Y. (2006) The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial. Annals of Internal Medicine, 145, 557-563.
https://doi.org/10.7326/0003-4819-145-8-200610170-00004
|
[26]
|
Pimentel, M., Lembo, A., Chey, W., Zakko, S., Ringel, Y., Yu, J., et al. (2011) Target Study Group. Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. The New England Journal of Medicine, 364, 22-32.
https://doi.org/10.1056/NEJMoa1004409
|
[27]
|
Pimentel, M., Chang, C., Chua, K., Mirocha, J., DiBaise, J., Rao, S., et al. (2014) Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome. Digestive Diseases and Sciences, 59, 1278-1285.
https://doi.org/10.1007/s10620-014-3157-8
|
[28]
|
Sharara, A.I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S. and Elhajj, I. (2006) A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence. The American Journal of Gastroenterology, 101, 326-333. https://doi.org/10.1111/j.1572-0241.2006.00458.x
|
[29]
|
Ford, A., Moayyedi, P., Lacy, B., Lembo, A., Saito, Y., Schiller, L., et al. (2014) Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. The American Journal of Gastroenterology, 109, S2-S26. https://doi.org/10.1038/ajg.2014.187
|
[30]
|
Menees, S., Maneerattannaporn, M., Kim, H. and Chey, W. (2012) The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology, 107, 28-35.
https://doi.org/10.1038/ajg.2011.355
|
[31]
|
Shah, E., Kim, S., Chong, K., Lembo, A. and Pimentel, M. (2012) Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome. American Journal of Medicine, 125, 381-393.
|
[32]
|
Pimentel, M., Chow, E.J. and Lin, H.C. (2003) Normalization of Lactulose Breath Testing Correlates with Symptom Improvement in Irritable Bowel Syndrome: A Double-Blind,Randomized, Placebo-Controlled Study The American Journal of Gastroenterology, 98, 412-419.
|
[33]
|
Posserud, I., Stotzer, P., Björnsson, E., Abrahamsson, H. and Simrén, M. (2007) Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome. Gut, 56, 802-808. https://doi.org/10.1136/gut.2006.108712
|
[34]
|
Kassinen, A., Krogius-Kurikka, L., Makivuokko, H., et al. (2007) The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly from That of Healthy Subjects. Gastroenterology, 133, 24-33.
https://doi.org/10.1053/j.gastro.2007.04.005
|
[35]
|
Pimentel, M. (2009) Review of Rifaximin as Treatment for SIBO and IBS. Expert Opinion on Investigational Drugs, 18, 349-358.
https://doi.org/10.1517/13543780902780175
|
[36]
|
Brigidi, P., Swennen, E., Rizzello, F., Bozzolasco, M. and Matteuzzi, D. (2002) Effects of Rifaximin Administration on the Intestinal Microbiota in Patients with Ulcerative Colitis. Journal of Chemotherapy, 14, 290-295.
https://doi.org/10.1179/joc.2002.14.3.290
|
[37]
|
Lotronex (Alosetron Hydrochloride) Tablets. Prometheus Laboratories, San Diego, 2008 (Package Insert).
|
[38]
|
Zelnorm (Tegaserod Maleate) Tablets. Novartis Pharmaceuticals, East Hanover, 2007 (Package Insert).
|
[39]
|
Amitiza (Lubiprostone) Capsules. Takeda Pharmaceuticals America, Deerfield, 2008 (Package Insert).
|